Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBIT (2016 - 2026)

Intellia Therapeutics has reported EBIT over the past 12 years, most recently at -$100.5 million for Q1 2026.

  • Quarterly EBIT rose 16.78% to -$100.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$420.7 million through Mar 2026, up 22.24% year-over-year, with the annual reading at -$441.0 million for FY2025, 17.46% up from the prior year.
  • EBIT was -$100.5 million for Q1 2026 at Intellia Therapeutics, down from -$98.7 million in the prior quarter.
  • Over five years, EBIT peaked at -$98.3 million in Q2 2022 and troughed at -$144.8 million in Q3 2024.
  • The 5-year median for EBIT is -$114.0 million (2024), against an average of -$120.5 million.
  • Year-over-year, EBIT crashed 210.71% in 2022 and then increased 27.66% in 2025.
  • A 5-year view of EBIT shows it stood at -$110.1 million in 2022, then decreased by 27.07% to -$139.9 million in 2023, then grew by 2.46% to -$136.4 million in 2024, then grew by 27.66% to -$98.7 million in 2025, then dropped by 1.85% to -$100.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's EBIT are -$100.5 million (Q1 2026), -$98.7 million (Q4 2025), and -$111.5 million (Q3 2025).